These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15257864)

  • 21. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on calcium antagonists and the kidney.
    Tobe S
    Curr Opin Nephrol Hypertens; 2003 May; 12(3):309-15. PubMed ID: 12698071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renoprotective effects of antihypertensive drugs.
    Preston RA
    Am J Hypertens; 1999 Jan; 12(1 Pt 2):19S-32S. PubMed ID: 10077416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure in diabetic nephropathy--current controversies.
    Ritz E; Rychlík I; Schömig M; Wagner J
    J Intern Med; 2001 Mar; 249(3):215-23. PubMed ID: 11293432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.
    Andersen NH; Mogensen CE
    Curr Hypertens Rep; 2002 Oct; 4(5):394-402. PubMed ID: 12217259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
    Eberhard R; Dikow R
    Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney.
    Thurman JM; Schrier RW
    Am J Med; 2003 May; 114(7):588-98. PubMed ID: 12753883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract]   [Full Text] [Related]  

  • 36. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
    Ritz E; Rychlík I; Miltenberger-Miltenyi G
    J Hypertens Suppl; 1998 Sep; 16(7):S17-22. PubMed ID: 9855027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
    Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
    Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate drug therapy for improving outcomes in diabetic nephropathy.
    Toto RD
    Curr Diab Rep; 2002 Dec; 2(6):545-52. PubMed ID: 12643162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.